The company malaria keeps: How co-infection with Epstein-Barr virus leads to endemic Burkitt lymphoma

Current Opinion in Infectious Diseases

Volumn 24, Issue 5, 2011, Pages 435-441

  Moormann, Ann M ^a   Snider, Cynthia J ^b   Chelimo, Kiprotich ^c  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b IL   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

B cell immunity; endemic Burkitt lymphoma; Epstein "Barr virus; malaria; T cell immunity

Indexed keywords

ANTIMALARIAL AGENT;

APOPTOSIS; B LYMPHOCYTE; BURKITT LYMPHOMA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; ENDEMIC DISEASE; EPSTEIN BARR VIRUS INFECTION; FLOW CYTOMETRY; HUMAN; IMMUNITY; INCIDENCE; MALARIA; MALARIA CONTROL; MIXED INFECTION; MORBIDITY; MORTALITY; NONHUMAN; PATHOGENESIS; PLASMODIUM FALCIPARUM; REVIEW; SEROLOGY; T LYMPHOCYTE; VIRUS LOAD; VIRUS REPLICATION;

BURKITT LYMPHOMA; COINFECTION; EPSTEIN-BARR VIRUS INFECTIONS; HERPESVIRUS 4, HUMAN; HUMANS; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; VIRUS ACTIVATION;

EID: 80052466750     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e328349ac4f     Document Type: Review

References (60)

1. World Malaria Report on World Wide Web. http://www.who.int/malaria/world- malaria-report-2010/en/index.html.
2. Moormann AM. How might infant and paediatric immune responses influence malaria vaccine efficacy? Parasite Immunol 2009; 31:547-559.
3. Haldar K, Mohandas N. Malaria, erythrocytic infection, and anemia. Hematology Am Soc Hematol Educ Program 2009; 87-93.
4. Dalldorf G, Linsell CA, Barnhart FE, et al. An epidemiologic approach to the lymphomas of African children and Burkitt's sacroma of the jaws. Perspect Biol Med 1964; 7:435-449.
5. Burkitt D. A sarcoma involving the jaws in African children. Br J Surg 1958; 46:218-223.
6. Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet 1964; 1:702-703.
7. Zur Hausen H, Schulte-Holthausen H, Klein G, et al. EBV DNA in biopsies of Burkitt tumours and anaplastic carcinomas of the nasopharynx. Nature 1970; 228:1056-1058.
8. Biggar RJ, Henle G, Bocker J, et al. Primary Epstein-Barr virus infections in African infants. II. Clinical and serological observations during seroconversion. Int J Cancer 1978; 22:244-250. (Pubitemid 9024590)
9. DeThe G, Geser A, Day NE, et al. Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature 1978; 274:756-761. (Pubitemid 8406152)
10. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 2008; 6:913-924.
11. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757-768. (Pubitemid 39331148)
12. Rochford R, Cannon MJ, Moormann AM. Endemic Burkitt's lymphoma: a polymicrobial disease? Nat Rev Microbiol 2005; 3:182-187. (Pubitemid 40207598)
13. Burkitt DP. Etiology of Burkitt's lymphoma: an alternative hypothesis to a vectored virus. J Natl Cancer Inst 1969; 42:19-28.
14. Morrow RH, Gutensohn N, Smith PG. Epstein-Barr virus-malaria interaction models for Burkitt's lymphoma: implications for preventive trials. Cancer Res 1976; 36:667-669.
15. Geser A, Brubaker G, Draper CC. Effect of a malaria suppression program on the incidence of African Burkitt's lymphoma. Am J Epidemiol 1989; 129:740-752. (Pubitemid 19094252)
16. Ogwang MD, Bhatia K, Biggar RJ, et al. Incidence and geographic distribution of endemic Burkitt lymphoma in northern Uganda revisited. Int J Cancer 2008; 123:2658-2663.
17. Rainey JJ, Omenah D, Sumba PO, et al. Spatial clustering of endemic Burkitt's lymphoma in high-risk regions of Kenya. Int J Cancer 2007; 120:121-127. (Pubitemid 44901926)
18. Mwanda OW, Rochford R, Moormann AM, et al. Burkitt's lymphoma in Kenya: geographical, age, gender and ethnic distribution. East Afr Med J 2004; 81(Suppl 8):S68-S77. (Pubitemid 41185456)
19. Rainey JJ, Mwanda WO, Wairiumu P, et al. Spatial distribution of Burkitt's lymphoma in Kenya and association with malaria risk. Trop Med Int Health 2007; 12:936-943. (Pubitemid 47245827)
20. Burkitt D, Wright D. Geographical and tribal distribution of the African lymphoma in Uganda. Br Med J 1966; 1:569-573.
21. Morrow RH, Kisuule A, Pike MC, et al. Burkitt's lymphoma in the Mengo Districts of Uganda: epidemiologic features and their relationship to malaria. J Natl Cancer Inst 1976; 56:479-483.
22. Hislop AD, Taylor GS, Sauce D, et al. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. Annu Rev Immunol 2007; 25:587-617. (Pubitemid 46697918)
23. Burrows SR, Moss DJ, Khanna R. Understanding human T-cell-mediated immunoregulation through herpesviruses. Immunol Cell Biol 2011; 89:352-358.
24. Moormann AM, Chelimo K, Sumba OP, et al. Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis 2005; 191:1233-1238.
25. Donati D, Espmark E, Kironde F, et al. Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis 2006; 193:971-977.
26. Njie R, Bell AI, Jia H, et al. The effects of acute malaria on Epstein-Barr virus (EBV) load and EBV-specific T cell immunity in Gambian children. J Infect Dis 2009; 199:31-38.
27. Rasti N, Falk KI, Donati D, et al. Circulating Epstein-Barr virus in children living in malaria-endemic areas. Scand J Immunol 2005; 61:461-465. (Pubitemid 40695017)
28. Yone CL, Kube D, Kremsner PG, et al. Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg 2006; 100:669-676.
29. Vossen MT, Westerhout EM, Soderberg-Naucler C, et al. Viral immune evasion: a masterpiece of evolution. Immunogenetics 2002; 54:527-542. (Pubitemid 35435511)
30. Klein E, Klein G, Levin PH. Immunological control of human lymphoma: discussion. Cancer Res 1976; 36:724-727.
31. Gunapala DE, Facer CA, Davidson R, et al. In vitro analysis of Epstein-Barr virus: host balance in patients with acute Plasmodium falciparum malaria. I: Defective T-cell control. Parasitol Res 1990; 76:531-535. (Pubitemid 20297613)
32. Moss DJ, Burrows SR, Castelino DJ, et al. A comparison of Epstein-Barr virusspecific T-cell immunity in malaria-endemic and-nonendemic regions of Papua New Guinea. Int J Cancer 1983; 31:727-732. (Pubitemid 13060776)
33. Whittle HC, Brown J, Marsh K, et al. T-cell control of Epstein-Barr virusinfected B cells is lost during P. falciparum malaria. Nature 1984; 312:449-450. (Pubitemid 15217838)
34. Gudgeon NH, Taylor GS, Long HM, et al. Regression of Epstein-Barr virusinduced B-cell transformation in vitro involves virus-specific CD8 T cells as the principal effectors and a novel CD4 T-cell reactivity. J Virol 2005; 79:5477-5488. (Pubitemid 40548216)
35. Moormann AM, Chelimo K, Sumba PO, et al. Exposure to holoendemic malaria results in suppression of Epstein-Barr virus-specific T cell immunosurveillance in Kenyan children. J Infect Dis 2007; 195:799-808. (Pubitemid 46363924)
36. Moormann AM, Heller KN, Chelimo K, et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFN-gamma T cell responses. Int J Cancer 2009; 124:1721-1726.
37. Chattopadhyay PK, Melenhorst JJ, Ladell K, et al. Techniques to improve the direct ex vivo detection of low frequency antigen-specific CD8 T cells with peptide-major histocompatibility complex class I tetramers. Cytometry A 2008; 73:1001-1009.
38. White MT, Griffin JT, Riley EM, et al. Efficacy model for antibody-mediated preerythrocytic malaria vaccines. Proc Biol Sci 2011; 278:1298-1305.
39. Corran P, Coleman P, Riley E, et al. Serology: a robust indicator of malaria transmission intensity? Trends Parasitol 2007; 23:575-582. (Pubitemid 350167541)
40. Drakeley CJ, Corran PH, Coleman PG, et al. Estimating medium-and longterm trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci USA 2005; 102:5108-5113.
41. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields virology. 5th ed. Vol. 2. Philadelphia, PA: Lippincott Williams & Wilkins; 2007.
42. Bergbauer M, Kalla M, Schmeinck A, et al. CpG-methylation regulates a class of Epstein-Barr virus promoters. PLoS Pathog 2010; 6:e1001114.
43. Asito AS, Piriou E, Odada PS, et al. Elevated anti-Zta IgG levels and EBV viral load are associated with site of tumor presentation in endemic Burkitt's lymphoma patients: a case control study. Infect Agent Cancer 2010; 5:13.
44. Biggar RJ, Gardiner C, Lennette ET, et al. Malaria, sex, and place of residence as factors in antibody response to Epstein-Barr virus in Ghana, West Africa. Lancet 1981; 2:115-118. (Pubitemid 11074963)
45. Lam KM, Syed N, Whittle H, et al. Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet 1991; 337:876-878.
46. Piriou E, Kimmel R, Chelimo K, et al. Serological evidence for long-term Epstein-Barr virus reactivation in children living in a holoendemic malaria region of Kenya. J Med Virol 2009; 81:1088-1093.
47. Abele DC, Tobie JE, Hill GJ, et al. Alterations in serum proteins and 19s antibody production during the course of induced malarial infections in man. Am J Trop Med Hyg 1965; 14:191-197.
48. Greenwood BM. Possible role of a B-cell mitogen in hypergammaglobulinaemia in malaria and trypanosomiasis. Lancet 1974; 1:435-436.
49. Whittle HC, Brown J, Marsh K, et al. The effects of Plasmodium falciparum malaria on immune control of B lymphocytes in Gambian children. Clin Exp Immunol 1990; 80:213-218. (Pubitemid 20147718)
50. Donati D, Zhang LP, Chene A, et al. Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun 2004; 72:5412-5418. (Pubitemid 39223429)
51. Chene A, Donati D, Guerreiro-Cacais AO, et al. A molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog 2007; 3:e80.
52. Lanzavecchia A, Sallusto F. Human B cell memory. Curr Opin Immunol 2009; 21:298-304.
53. Radbruch A, Muehlinghaus G, Luger EO, et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol 2006; 6:741-750. (Pubitemid 44453460)
54. Tarlinton D, Radbruch A, Hiepe F, et al. Plasma cell differentiation and survival. Curr Opin Immunol 2008; 20:162-169.
55. Weiss GE, Traore B, Kayentao K, et al. The Plasmodium falciparum-specific human memory B cell compartment expands gradually with repeated malaria infections. PLoS Pathog 2010; 6:e1000912.
56. Wykes M, Good MF. Memory B cell responses and malaria. Parasite Immunol 2006; 28:31-34.
57. Klein G, Klein E, Kashuba E. Interaction of Epstein-Barr virus (EBV) with human B-lymphocytes. Biochem Biophys Res Commun 2010; 396:67-73.
58. Richard Y, Amiel C, Jeantils V, et al. Changes in blood B cell phenotypes and Epstein-Barr virus load in chronically human immunodeficiency virus-infected patients before and after antiretroviral therapy. J Infect Dis 2010; 202:1424-1434.
59. Asito AS, Moormann AM, Kiprotich C, et al. Alterations on peripheral B cell subsets following an acute uncomplicated clinical malaria infection in children. Malar J 2008; 7:238.
60. Leucci E, Onnis A, Cocco M, et al. B-cell differentiation in EBV-positive Burkitt lymphoma is impaired at posttranscriptional level by miRNA-altered expression. Int J Cancer 2010; 126:1316-1326.